Table 2 Base-case scenario results
Outcomes | Current US strategy | Genetically guided strategy | Clozapine substitution strategy |
|---|---|---|---|
Cumulative mortality (%) | 1.70 (1.48–1.92) | 1.71 (1.49–1.93) | 1.78 (1.54–2.02) |
Mean survival time per patient adjusted for quality of life (quality-adjusted life-days) | 669.9 (618.4–719.1) | 669.8 (618.3–719.0) | 660.2 (603.7–713.7) |
Cost per patient (US$) | |||
Total | $13,694 (7752–19,626) | $13,091 (7154–19,023) | $13,738 (7240–20210) |
Sepsis | $98 (60–140) | $163 (100–230) | $123 (73–180) |
Clozapine treatment | $1453 (1442–1464) | $1453 (1442–1464) | $1234 (1157–1301) |
Substitute treatment | $11 122 (5189–17,057) | $11,120 (5188–17,052) | $12,181 (5671–18,648) |
ANCM | $1021 (1015–1027) | $154 (108–207) | 0 |
Genetic testing | 0 | $200 | $200 |
ICER (million US$ per QALY)a | $3.93 (2.01–8.17) | Dominated | |
